Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Clears Amgen’s Imlygic At Second Attempt, Combo Results Keenly Awaited

Executive Summary

A completely new form of therapy, the use of viruses to kill cancer cells, is now recommended by NICE for use in melanoma patients in England in final draft guidance, although its future therapeutic and commercial success may depend on positive findings from ongoing combination studies with checkpoint inhibitors and other immunotherapies.

Advertisement

Related Content

Deal Watch: Bristol And Otsuka Pursue Oncolytic Virus Therapies Via Licensing Deals
Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda
Discounts Sway NICE As Novartis Outlines Concerns Over New Cancer Drugs Fund
Transgene Secures Two Year Runway As Oncolytic Vaccine Enters Phase III
Amgen's Imlygic 1st FDA-Approved Oncolytic Virus Therapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097087

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel